# Chik Wai Chiew

> Chik Wai Chiew is a Series C investor at Tembusu Partners backing Health Care and Education. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Tembusu Partners](https://shizune.co/investors/profile/tembusu-partners)
- Total investments: 10
- Last investment: Aug 2024
- Lead investor: 70%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/wai-chiew-chik-a7654542

Chik Wai Chiew is a Series C investor at Tembusu Partners focused on Health Care and Education. Wai Chiew is a Partner of Tembusu Partners. He has more than 15 years’ experience in private and public equity investments; strategy and business development with global companies and organisations, having been based in New York, Geneva, Shanghai and Singapore. Prior to joining Tembusu, Wai Chiew has held various positions in Temasek Holdingsincluding Chief Representative of Shanghai office; GM, Shanghai Investment Consulting WFOE; Director Investments, and has led strategic relations, investments and portfolio management in China and Latin America. He has also advised institutional and start-up funds, growth companies and new ventures on investment and business strategy as well as fund raising, and served on the boards of several China-based companies and advisory committees of leading PE funds.Wai Chiew’s public sector experience was with Singapore Economic Development Board (EDB) where he held various positions in strategic planning, industry development, and international operations, and his not-for-profit experience was with World Economic Forum based in Geneva, undertaking India and China research and scenario planning projects.Wai Chiew was awarded the Glaxo-EDB scholarship and holds a BA in Economics from Cambridge University, UK; MA from Yale University, USA; and completed EMBA (conducted in Mandarin) from Cheung Kong Graduate School of Business based in China.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 30% |
| Education | 2 | 20% |
| Apps | 1 | 10% |
| Coffee | 1 | 10% |
| EdTech | 1 | 10% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 30% |
| Seed | 2 | 20% |
| Series A | 2 | 20% |
| Venture - Series Unknown | 2 | 20% |
| Series B | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Singapore | 3 | 30% |
| India | 2 | 20% |
| Indonesia | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kreedo Early Childhood Solutions | Kreedo provides a complete preschool solution. | $4M | Series A | Aug 27, 2024 |  |
| The Gentle Group | SilverConnect is a medical nutrition startup creating specialized food solutions for people with dysphagia. Dysphagia, or the difficulty to swallow, is more common in older people and often results from nerve or muscle problems. | $2M | Venture - Series Unknown | Jul 08, 2024 |  |
| Bettr Group | Bettr Group is a coffee company that wholesales and retails coffee bars and equipment. | $1.5M | Seed | Oct 13, 2023 |  |
| Cakap | Cakap is an upskilling platform that enables 2-way learning interactions between students and professional teachers. Cakap is an application that enables a 2-way interaction between life-skill learners and professional tutors around the Asia Pacific via video call and text conversation. CAKAP delivers high-quality education that is accessible,acceptable, affordable for people. and will be able to elevate people’s lives by enabling skill enhancement for everyone, from anywhere, at any time. | $7.5M | Series C | Apr 12, 2023 |  |
| mfine | Mfine is an health-tech startup that offers an AI-powered online doctor consultation app. Their doctors have access to a proprietary Assistive Intelligence platform that can analyze the symptoms and deliver accurate prognosis for the specialist to assess patients. This means, the doctor knows about patients' condition even before they’ve seenthem, making the diagnosis quicker and sharper.Mfine aims to make access to trusted healthcare simple, fast and proactive. With a combination of new-age technology and partnerships with best in class hospitals/clinics, they designed mfine keeping consumer experience at its core. Mfine brings in instant and continuous connectivity with top doctors of the best hospitals. It uses cutting edge technology to keep track of your health parameters and keep all your health data in your control and easily accessible. Digital wearable devices, mobile app, and at-home services bring in the much-needed convenience and speed in getting you the right care when you need it.Mfine was founded in 2017 and is based in Bengaluru. | $48.8M | Series C | Aug 31, 2021 |  |
| Hummingbird Bioscience | Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association,including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas. | $125M | Series C | May 18, 2021 |  |
| mfine | Mfine is an health-tech startup that offers an AI-powered online doctor consultation app. Their doctors have access to a proprietary Assistive Intelligence platform that can analyze the symptoms and deliver accurate prognosis for the specialist to assess patients. This means, the doctor knows about patients' condition even before they’ve seenthem, making the diagnosis quicker and sharper.Mfine aims to make access to trusted healthcare simple, fast and proactive. With a combination of new-age technology and partnerships with best in class hospitals/clinics, they designed mfine keeping consumer experience at its core. Mfine brings in instant and continuous connectivity with top doctors of the best hospitals. It uses cutting edge technology to keep track of your health parameters and keep all your health data in your control and easily accessible. Digital wearable devices, mobile app, and at-home services bring in the much-needed convenience and speed in getting you the right care when you need it.Mfine was founded in 2017 and is based in Bengaluru. | $16M | Venture - Series Unknown | Jan 18, 2021 |  |
| The Gentle Group | SilverConnect is a medical nutrition startup creating specialized food solutions for people with dysphagia. Dysphagia, or the difficulty to swallow, is more common in older people and often results from nerve or muscle problems. |  | Seed | Jun 22, 2020 |  |
| Hummingbird Bioscience | Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association,including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas. | $25M | Series B | Dec 05, 2019 |  |
| Hummingbird Bioscience | Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association,including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas. |  | Series A | Jul 10, 2019 |  |

10 of 10 investments shown.

## Co-investors
- [Seeds Capital](https://shizune.co/investors/profile/seeds-capital) — VC Fund, 5 deals together
- [1Crowd](https://shizune.co/investors/profile/1crowd) — VC Fund, 2 deals together
- [Alteria Capital](https://shizune.co/investors/profile/alteria-capital) — VC Fund, 2 deals together
- [BEENEXT](https://shizune.co/investors/profile/bee-next) — VC Fund, 2 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 2 deals together
- [SBI Investment](https://shizune.co/investors/profile/sbi-investment-2) — VC Fund, 2 deals together

## About Tembusu Partners

VC Fund · Singapore, Singapore

Established in 2006, Tembusu Partners is a boutique private equity firm in Singapore dedicated to supporting high growth ventures across Emerging Asia.Leveraging our strategic location at the heart of Asia, we specialise in venture and growth-stage investments in fast-growing markets of Greater China, India, and Southeast Asia. Our deepunderstanding of markets, investment cycles and complex cultural nuances grants us clarity and insight in making our investments. We manage capital from our investors and partners across Asia, Europe, and America. To date, we have completed more than S$300 million worth of private equity transactions.Tembusu invests in disruptive technology that we believe have strong potential to drive innovation in key focus sectors such as financial and business services, consumer services, education and healthcare. With an advisory board and investment committee comprising well-connected corporate leaders and industry veterans ranging from technology to business services, we are committed to supporting founders and companies in their global growth.

5 contacts available at Tembusu Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Andy Lim | Chairman & Founder | https://shizune.co/investors/profile/andy-lim-2 |
| Chik Wai Chiew | Partner | https://shizune.co/investors/profile/chik-wai-chiew |
| Chik Wai Chiew | Partner | https://shizune.co/investors/profile/chik-wai-chiew-11da |
| Brijesh Pande | Managing Partner | https://shizune.co/investors/profile/brijesh-pande |
| Emily Zhang | Director (China) | https://shizune.co/investors/profile/emily-zhang-2 |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Chik Wai Chiew invest in?

Chik Wai Chiew invests primarily in Health Care, Education and Apps startups, most often at Series C and Seed stage. Most of the 10 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chik Wai Chiew last invest?

The most recent investment recorded for Chik Wai Chiew closed in Aug 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co